Literature DB >> 3016174

Desensitization of beta-adrenergic receptor-coupled adenylate cyclase in cerebral cortex after in vivo treatment of rats with desipramine.

F Okada, Y Tokumitsu, M Ui.   

Abstract

Continuous treatment (1-10 days) of rats with desipramine (10 mg/kg, twice per day) caused desensitization of the beta-adrenergic receptor-coupled adenylate cyclase system of cerebral cortical membranes. The decrease in the isoproterenol-stimulated adenylate cyclase activity was more rapid and greater than the decrease in the number of beta-adrenergic receptors in membranes during treatment of the membrane donor rats with desipramine, indicating that the desensitization occurring at an early stage of the treatment was not accounted for solely by the decrease in the receptor number. Neither the guanine nucleotide regulatory protein (N) nor the adenylate cyclase catalyst was impaired by the drug treatment, since there was no decrease in the cyclase activity measured in the presence or absence of GTP, guanyl-5'-yl-beta-gamma-imidodiphosphate [Gpp(NH)p], NaF, or forskolin. Gpp(NH)p-induced activation of membrane adenylate cyclase developed with a lag time of a few minutes in membranes from control or drug-treated rats. The lag was shortened by the addition of isoproterenol, indicating that beta-receptors were coupled to N in such a manner as to facilitate the exchange of added Gpp(NH)p with endogenous GDP on N. This effect of isoproterenol rapidly decreased during the drug treatment of rats. Thus, functional uncoupling of the N protein from receptors was responsible for early development of desensitization of beta-adrenergic receptor-mediated adenylate cyclase in the cerebral cortex during desipramine therapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3016174     DOI: 10.1111/j.1471-4159.1986.tb04522.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

Review 1.  Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system.

Authors:  G B Baker; A J Greenshaw
Journal:  Cell Mol Neurobiol       Date:  1989-03       Impact factor: 5.046

2.  Chronic administration of l-sulpiride at non-neuroleptic doses reduces the duration of immobility in experimental models of "depression-like" behavior.

Authors:  A V Vergoni; A Forgione; A Bertolini
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

3.  The serotonin/noradrenaline-link in brain. I. The role of noradrenaline and serotonin in the regulation of density and function of beta adrenoceptors and its alteration by desipramine.

Authors:  D H Manier; D D Gillespie; E Sanders-Bush; F Sulser
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-02       Impact factor: 3.000

4.  In vitro and ex vivo effects of antidepressants on rat brain membrane-bound phosphatidylinositol synthetase activity.

Authors:  P P Li; J J Warsh; N Z Stanacev
Journal:  Neurochem Res       Date:  1988-08       Impact factor: 3.996

Review 5.  New perspectives on the molecular pharmacology of affective disorders.

Authors:  F Sulser
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

Review 6.  G protein-coupled receptors in major psychiatric disorders.

Authors:  Lisa A Catapano; Husseini K Manji
Journal:  Biochim Biophys Acta       Date:  2006-10-03

7.  Heterotrimeric g proteins: insights into the neurobiology of mood disorders.

Authors:  Javier González-Maeso; J Javier Meana
Journal:  Curr Neuropharmacol       Date:  2006-04       Impact factor: 7.363

8.  Photoactivation of intracellular guanosine triphosphate analogues reduces the amplitude and slows the kinetics of voltage-activated calcium channel currents in sensory neurones.

Authors:  A C Dolphin; J F Wootton; R H Scott; D R Trentham
Journal:  Pflugers Arch       Date:  1988-06       Impact factor: 3.657

9.  Independent regulation of beta 1- and beta 2-adrenoceptors.

Authors:  M Beer; S Hacker; J Poat; S M Stahl
Journal:  Br J Pharmacol       Date:  1987-12       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.